Company Encyclopedia
View More
name
NUCIEN PHARMA
688189.SH
Hunan Nucien Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research and development, production, and sale of chemical drugs in China. The company also focuses on the research, development, production, and sales of antiviral drugs, including influenza and infectious disease prevention and treatment drugs, as well as medicines for anti-influenza, malignant tumors, cardiovascular, antibiotics, antipyretics, pain relief, diabetes, analgesic, cerebrovascular, respiratory, and other pharmaceutical fields. Hunan Nucien Pharmaceutical Co., Ltd. was founded in 2006 and is based in Guangzhou, China.
3.095 T
688189.SHMarket value -Rank by Market Cap -/-

Financial Score

28/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking217/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-35.04%E
    • Profit Margin-386.37%E
    • Gross Margin28.53%C
  • Growth ScoreE
    • Revenue YoY-76.70%E
    • Net Profit YoY-435.86%E
    • Total Assets YoY-24.45%E
    • Net Assets YoY-33.82%E
  • Cash ScoreE
    • Cash Flow Margin-25.88%D
    • OCF YoY-76.70%E
  • Operating ScoreE
    • Turnover0.08E
  • Debt ScoreA
    • Gearing Ratio22.57%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    NUCIEN PHARMA terminates the planning of major asset restructuring matters

    NUCIEN PHARMA announced the termination of the significant asset restructuring with Future Pharma. The company had planned to acquire the target asset group of Future Pharma in cash, but after multiple discussions and negotiations, they failed to reach an agreement on the core terms of the transaction. To protect the interests of the company and its shareholders, the parties involved decided to terminate the transaction and signed the "Acquisition Termination Agreement."

    Zhitong·
    SH
    688189
    -1.71%
    Zhitong·
    SH
    688189
    -1.71%

    NUCIEN PHARMA received the "Notice of Case Filing" from the China Securities Regulatory Commission

    According to the Zhitong Finance APP, NUCIEN PHARMA announced that the company recently received a "Notice of Case Filing" (No.: Zhen Jian Li An Zi 0132025024) issued by the China Securities Regulatory Commission (CSRC). Due to the company's suspected violations of annual report information disclosure, the CSRC has decided to file a case against the company in accordance with the Securities Law of the People's Republic of China, the Administrative Penalty Law of the People's Republic of China, and other laws and regulations

    Zhitong·
    SH
    688189
    -1.71%
    Zhitong·
    SH
    688189
    -1.71%

    NUCIEN PHARMA: Guangzhou Qianyuan plans to reduce its holdings by no more than 3% of shares

    According to the Zhitong Finance APP, NUCIEN PHARMA announced that due to funding needs, Guangzhou Qianyuan plans to reduce its holdings of the company's shares through centralized bidding and block trading. This reduction plan will be carried out within three months after the disclosure date of this reduction plan, with a total reduction of no more than 8.232 million shares, accounting for no more than 3% of the company's total share capital

    Zhitong·
    SH
    688189
    -1.71%
    Zhitong·
    SH
    688189
    -1.71%

    NUCIEN PHARMA: Net profit loss of 40.0223 million yuan in the first half of 2025

    NUCIEN PHARMA announced that its operating revenue in the first half of 2025 was 61.8463 million yuan, a year-on-year decrease of 71.28%. The net profit loss was 40.0023 million yuan, compared to a net profit of 10.1727 million yuan in the same period last year

    Zhitong·
    SH
    688189
    -1.71%
    Zhitong·
    SH
    688189
    -1.71%

    NUCIEN PHARMA plans to acquire the target asset group held by Future Medicine for no more than 480 million yuan to enrich the company's product pipeline

    NUCIEN PHARMA plans to acquire a target asset group held by Future Pharma for cash not exceeding 480 million yuan, including various trace element injection solutions (I, II, III) and related intellectual property rights. This transaction is expected to constitute a significant asset restructuring, enrich the company's product pipeline, optimize the layout of "anti-infection - chronic disease - nutritional support," align with the "big health" development strategy, and bring revenue and profit growth to the company

    Zhitong·
    SH
    688189
    -1.71%
    Zhitong·
    SH
    688189
    -1.71%
    © 2025 Longbridge｜Disclaimer